Investors Buy High Volume of Nuvation Bio Call Options (NYSE:NUVB)

Nuvation Bio Inc. (NYSE:NUVB) was the target of unusually large options trading activity on Monday. Stock investors bought 2,985 call options on the stock. This represents an increase of 227% compared to the average daily volume of 913 call options.

Insider Activity at Nuvation Bio

In other news, Director Robert Mashal acquired 25,000 shares of the business’s stock in a transaction on Tuesday, June 9th. The shares were acquired at an average cost of $4.73 per share, with a total value of $118,250.00. Following the transaction, the director owned 225,000 shares in the company, valued at $1,064,250. The trade was a 12.50% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Kerry Wentworth sold 63,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $6.02, for a total value of $379,260.00. Following the transaction, the insider owned 53,000 shares in the company, valued at $319,060. This trade represents a 54.31% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 235,668 shares of company stock valued at $1,419,495. 30.11% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Nuvation Bio

Institutional investors and hedge funds have recently modified their holdings of the stock. Rangeley Capital LLC bought a new position in Nuvation Bio in the 2nd quarter worth about $25,000. Parallel Advisors LLC increased its stake in Nuvation Bio by 51.9% during the 3rd quarter. Parallel Advisors LLC now owns 7,597 shares of the company’s stock valued at $28,000 after purchasing an additional 2,597 shares in the last quarter. Cetera Investment Advisers bought a new stake in Nuvation Bio during the 2nd quarter valued at about $29,000. Captrust Financial Advisors purchased a new position in Nuvation Bio in the second quarter worth about $32,000. Finally, KBC Group NV purchased a new position in Nuvation Bio in the first quarter worth about $37,000. 61.67% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

NUVB has been the subject of a number of research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nuvation Bio in a report on Tuesday, April 21st. Truist Financial boosted their target price on shares of Nuvation Bio from $12.00 to $13.00 and gave the company a “buy” rating in a report on Tuesday, July 7th. Citigroup reaffirmed a “market outperform” rating on shares of Nuvation Bio in a research report on Wednesday, June 10th. Wedbush reaffirmed an “outperform” rating and issued a $11.00 target price on shares of Nuvation Bio in a research report on Tuesday, May 5th. Finally, Royal Bank Of Canada decreased their price target on shares of Nuvation Bio from $20.00 to $19.00 and set an “outperform” rating for the company in a research note on Tuesday, July 7th. Eight equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Nuvation Bio has an average rating of “Moderate Buy” and a consensus target price of $12.38.

Nuvation Bio Stock Performance

Shares of NUVB opened at $6.27 on Tuesday. The company has a quick ratio of 7.24, a current ratio of 7.44 and a debt-to-equity ratio of 0.15. The stock has a market cap of $2.18 billion, a P/E ratio of -14.57 and a beta of 1.52. The business’s 50 day moving average price is $5.24 and its 200-day moving average price is $5.35. Nuvation Bio has a 52 week low of $2.18 and a 52 week high of $9.75.

Nuvation Bio (NYSE:NUVB) last posted its quarterly earnings data on Monday, May 4th. The company reported $0.01 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.04. The company had revenue of $83.23 million during the quarter, compared to analyst estimates of $66.22 million. Nuvation Bio had a negative return on equity of 44.10% and a negative net margin of 102.06%. Equities research analysts anticipate that Nuvation Bio will post -0.39 earnings per share for the current fiscal year.

About Nuvation Bio

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.